Skip to Content

MRD analysis in 1L Treatment of CLL in Elderly or Unfit patients

In this MEDtalk Talha Munir, Department of Haematology, St James’s University Hospital, Leeds, United Kingdom, presents the results of the Glow Study. In this study Ibrutinib plus venetoclax demonstrated superior uMRD responses that were deeper and better sustained post-treatment vs chlorambucil plus Obinutuzumab in elderly or unfit patients with previously untreated CLL.

Talha Munir

Få adgang til artiklen

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top